Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma.

Journal of cancer research and clinical oncology - 1 May 2021

Liu Zimin, Shi Mingpeng, Li Xiaoxiao, Song Shanai, Liu Ning, Du Haiwei, Ye Junyi, Li Haiyan, Zhang Zhou, Zhang Lu

Abstract excerpt

PURPOSE: The identification of HER2 overexpression in a subset of gastric adenocarcinoma (GA) patients represents a significant step forward in unveiling the molecular complexity of this disease. The predictive and prognostic value of HER2 amplification in advanced HER2 inhibitor-treated GA patients has been investigated. However, its predictive value in resectable patients remains elusive. METHODS: We enrolled...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to DNA Copy Number Variations

Share to Gene Amplification

Share to Prognosis

Share to Receptor, ErbB-2

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33543328
DOI: 10.1007/s00432-021-03522-9
PMCID: PMC8021510

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma.PMID 33543328Read ↗

Association of ERBB2 Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric CancerSemantic proximity Read ↗

Molecular characteristics of gastric cancer with ERBB2 amplificationSemantic proximity Read ↗

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.Semantic proximity Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

Estimating copy number using next-generation sequencing to determine ERBB2 amplification statusSemantic proximity Read ↗

HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteriaSemantic proximity Read ↗

HER2 Amplification and PD-L1 Expression in Advanced Gastric Cancer: Correlations, Clinical Implications, and Molecular CharacteristicsSemantic proximity Read ↗

Difference of molecular alterations in HER2-positive and HER2-negative gastric cancers by whole-genome sequencing analysisSemantic proximity Read ↗

HER2/ERBB2 copy number analysis by targeted next-generation sequencing in breast cancerSemantic proximity Read ↗

Genomic correlations for clinical outcomes in HER2-positive advanced gastric cancers treated using trastuzumab-based therapySemantic proximity Read ↗

High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection.Semantic proximity Read ↗

Genomic characterization between HER2-positive and negative gastric cancer patients in a prospective trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.